Oppenheimer Analysts Give Heron Therapeutics (NASDAQ:HRTX) a $34.00 Price Target

Heron Therapeutics (NASDAQ:HRTX) has been assigned a $34.00 price objective by Oppenheimer in a research report issued to clients and investors on Monday, March 19th. The firm currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price target indicates a potential upside of 16.84% from the company’s current price. Oppenheimer also issued estimates for Heron Therapeutics’ FY2019 earnings at ($0.23) EPS, FY2020 earnings at $1.22 EPS, FY2021 earnings at $3.30 EPS and FY2022 earnings at $5.03 EPS.

A number of other analysts have also weighed in on the stock. Mizuho reiterated a “buy” rating and issued a $28.00 price objective on shares of Heron Therapeutics in a research note on Friday, December 8th. Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Monday, January 15th. BidaskClub raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 20th. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Zacks Investment Research downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $35.92.

How to Become a New Pot Stock Millionaire

Shares of Heron Therapeutics stock opened at $29.10 on Monday. Heron Therapeutics has a 12-month low of $12.70 and a 12-month high of $32.70. The company has a market cap of $1,888.80, a price-to-earnings ratio of 7.97 and a beta of 1.86.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.29). The business had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.00 million. Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. equities research analysts expect that Heron Therapeutics will post -2.5 earnings per share for the current fiscal year.

In other news, VP Kimberly Manhard sold 18,000 shares of the firm’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $30.00, for a total value of $540,000.00. Following the transaction, the vice president now directly owns 18,000 shares of the company’s stock, valued at $540,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kevin C. Tang acquired 192,308 shares of the business’s stock in a transaction that occurred on Thursday, March 29th. The shares were purchased at an average price of $26.00 per share, with a total value of $5,000,008.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 218,000 shares of company stock worth $5,990,000. Insiders own 19.93% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Ellington Management Group LLC acquired a new stake in Heron Therapeutics during the fourth quarter worth about $195,000. Pinnacle Associates Ltd. acquired a new stake in Heron Therapeutics during the fourth quarter worth about $201,000. Trexquant Investment LP acquired a new stake in shares of Heron Therapeutics during the third quarter valued at about $206,000. Jefferies Group LLC acquired a new stake in shares of Heron Therapeutics during the fourth quarter valued at about $214,000. Finally, Jane Street Group LLC acquired a new stake in shares of Heron Therapeutics during the third quarter valued at about $223,000. Hedge funds and other institutional investors own 97.40% of the company’s stock.

WARNING: “Oppenheimer Analysts Give Heron Therapeutics (NASDAQ:HRTX) a $34.00 Price Target” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/04/11/heron-therapeutics-hrtx-pt-set-at-34-00-by-oppenheimer.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply